Welcome to our dedicated page for RELMADA THERAPEUTICS SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.
Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.
Relmada Therapeutics director John Glasspool reported a new equity award in the form of stock appreciation rights. On 12/12/2025, he was granted 164,000 stock appreciation rights with a conversion or exercise price of $4.06, each tied to one share of Relmada common stock.
The award is structured as a long-term incentive. It begins vesting on March 12, 2026, in 16 equal quarterly installments and expires on 12/12/2035. Following this grant, Glasspool beneficially owns 164,000 derivative securities directly, all linked to Relmada’s common stock.
Relmada Therapeutics director and COO Paul Kelly reported receiving 828,000 stock appreciation rights tied to the company’s common stock. These rights were granted on December 12, 2025 with an exercise price of $4.06 and expire on December 12, 2035.
The stock appreciation rights vest in 16 equal quarterly installments starting March 12, 2026, so portions of the award become exercisable over time. After this grant, Kelly beneficially owns 828,000 derivative securities directly, linking part of his compensation to Relmada’s future share performance.
Relmada Therapeutics, Inc. reported an insider equity award to one of its directors. On 12/12/2025, the director received stock appreciation rights tied to 164,000 shares of common stock with a base price of $4.06 per share.
These stock appreciation rights begin vesting in 16 equal quarterly installments starting on March 12, 2026, and are scheduled to expire on December 12, 2035. The award was reported as directly owned by the director.
Relmada Therapeutics, Inc. reported that its Board of Directors approved amended and restated employment agreements for its executive officers on December 12, 2025. The updated contracts cover Chief Executive Officer Sergio Traversa, Chief Operating Officer Paul Kelly, Chief Financial Officer Maged Shenouda, and Chief Accounting and Compliance Officer Charles Ence, and are stated to become effective as of January 1, 2026. The company explains that, except for the revisions reflected in these new agreements, the material terms remain the same as those previously described in earlier SEC disclosures, and the complete agreements are filed as exhibits.
Relmada Therapeutics (RLMD) furnished an update and preliminary, unaudited quarterly financial results via a press release and scheduled a conference call to discuss them. The company plans to file complete unaudited financial statements and notes in its upcoming Form 10‑Q.
The press release was provided as Exhibit 99.1 and a refreshed corporate presentation as Exhibit 99.2. Under the furnished status, this information is not deemed filed under the Exchange Act except as specifically incorporated by reference. A conference call and webcast were set for November 13, 2025 at 4:30 PM ET to review the update and results.
Relmada Therapeutics (RLMD) filed its Q3 2025 10‑Q showing narrower losses and a refocused pipeline. Operating expenses fell to $10.3 million from $23.0 million a year ago, driving a net loss of $10.1 million versus $21.7 million. For the nine months, the net loss was $37.5 million, with operating cash outflow of $31.2 million. At September 30, cash was $1.38 million and short‑term investments were $12.50 million.
The company alleviated going‑concern uncertainty after closing an underwritten offering on November 5 for 40.14 million shares and 5.32 million pre‑funded warrants, generating approximately $94 million in net proceeds (before other expenses, excluding warrant exercises). Nasdaq confirmed minimum bid price compliance on September 15.
Pipeline shifted to two assets: NDV‑01 (intravesical gemcitabine/docetaxel) in Phase 2 for NMIBC showed a 92% “anytime” complete response among 25 evaluable patients and secured FDA alignment to pursue two Phase 3 studies, targeted to begin in H1 2026. Sepranolone was acquired for €3.0 million (with $2.756 million paid) and is expected to enter a Phase IIb study in Prader‑Willi Syndrome in H1 2026. Earlier esmethadone and psilocybin programs were terminated.
Relmada Therapeutics (RLMD) filed a Form 4 showing an insider purchase. The company’s Chief Financial Officer, Maged Shenouda, purchased 500,000 shares of common stock on 11/05/2025 at a price of $2.2 per share, coded “P” for purchase.
Following the transaction, beneficial ownership stood at 788,335 shares, reported as direct ownership. The filing reflects a personal share acquisition by a senior officer and updates the executive’s current holdings.
Relmada Therapeutics (RLMD) Form 4: An officer serving as CAO and COO reported an open-market purchase (transaction code P) of 136,000 shares of common stock on 11/05/2025 at $2.2 per share. Following the transaction, the reporting person beneficially owns 403,931 shares, held directly. The filing indicates a single reporting person and relates to Relmada Therapeutics, Inc.
Relmada Therapeutics (RLMD) insider activity: Chief Executive Officer and Director Sergio Traversa reported a purchase of 272,500 shares of Common Stock on 11/05/2025 at $2.2 per share (transaction code P).
Following the trade, he beneficially owns 1,272,500 shares, held directly. This Form 4 reflects an open-market or private purchase and updates his direct ownership position.
Relmada Therapeutics (RLMD) insider activity: Chief Operating Officer and Director Paul Kelly purchased 90,000 shares of common stock at $2.2 on 11/05/2025. Following the transaction, he directly beneficially owns 502,295 shares.